. 2011 Aug 26;6(8):e23395. doi: 10.1371/journal.pone.0023395

Table 2. Combinatorial chemopreventive effect of Res and/or BTP on tumor regression.

Groups	Treatment	Number of animals with tumors		CNT		ANT(Mean ± SD)		ATV(Mean ± SD)
		18th	26th	18th	26th	18th	26th	18th	26th
II	DMBA+TPA	25/25	25/25	230	198	9.2±2.6	7.92±2.1	130.0±10.2	105.4±10.4
IV A	(−)Res-Non-tumor bearing	0/12	0/12	-	-	-	-	-	-
IV B	(−)Res-tumor bearing	6/6	6/6	34^a	28^a	5.66±1.9^a	5.66±2.0^a	56.1±7.2^a	51.8±6.0^a
IV C	(+)Res-tumor bearing	7/7	7/7	35^a	26^a	5.00±1.1^a	3.71±2.5^a	49.1±6.1^a	40.3±5.5^a
V A	(−)BTP-Non-tumor bearing	0/9	0/9	-	-	-	-	-	-
V B	(−)BTP-tumor bearing	8/8	8/8	42^a	36^a	5.25±2.1^a	4.5±2.2^a	59.3±6.2^a	50.8±6.6^a
V C	(+)BTP-tumor bearing	8/8	8/8	46^a	34^a	5.75±2.1^a	4.2±2.6^a	67.1±5.4^a	53.6±7.5^a
VI A	(−)Res+BTP-Non-tumor bearing	0/13	0/13	-	-	-	-	-	-
VI B	(−)Res+BTP-tumor bearing	5/5	5/5	13^b	10^b	2.6±2.0^b	2.0±2.0^c	24.2±5.4^b	21.8±5.6^c
VI C	(+)Res+BTP-tumor bearing	5/5	3/5	12^b	6^b	2.4±1.6^b	2.0±1.6^c	23.9±7.4^b	18.9±8.6^c

significant reduction over DMBA and TPA treated group II at 18th week (p<0.01).

significant reduction over BTP and Res alone treated groups IV B–C and V B–C at 18th week (p<0.01).

significant reduction at 26th week (p<0.01).

(−) indicates without treatment, (+) indicates with treatment.

Res, resveratrol; CNT, cumulative number of tumors; ANT, average number of tumors/mouse; ATV, average tumor volume/tumor bearing mouse.